Chapter 728: Frenzy For The Research Zones

The countries that did their calculations and saw that they qualified, were the first to start submitting their proposal. It didn’t matter if they were a large country or not, they all submitted their proposal.

And while the battle for the Nova Medical Centers was going on, another one was going on for the space station research zones. But this was far less intense than it was for the center.

After the rental application portal opened, they saw that Nova Technologies added images and a lengthy video to each zones categories, to possibly help the future renters to visually understand what it contains, not just from words on screens.

Each images also had explanation of its content captioned under them. This was the same with the video but it wasn’t caption. Rather, it was given audio explanation.

This made things better and easier for the countries, universities, research organizations and companies that intend to rent a zone. They could see what they would be paying for and it will incite their desire to have one to themselves.

Even without the images and videos for visualisation aid, just the fact that it’s a research facility built by Nova Technologies is already enough reason for organizations to want it. But the visuals made those arguments even more sound.

The value of the research zones was immense, and the deeper anyone looked, the clearer it became why.

It began with the environment itself, the thing no laboratory on Earth could offer at any price. Every zone carried microgravity bays where gravity could be switched off entirely, and to the people who understood what that meant, it was worth more than the lease.

In microgravity, proteins crystallized into structures of a perfection Earth’s gravity made impossible, and a protein’s exact structure was the map from which drugs were designed.

Materials that separated under gravity mixed cleanly without it. Optical fibers grew flawless. Cells grew into true three-dimensional tissue instead of flattening into sheets. Crystals formed without a single defect. These were not curiosities. They were the frontier edges of pharmaceuticals, of materials science, of semiconductors and tissue engineering, and each one had sat just out of reach of Earth-bound research for as long as anyone had known to want it.

But the environment was only half of it, and the sharper organizations understood that the other half was the larger prize. The zones were not empty rooms with the gravity turned off. They were built by Nova Technologies, which meant they came filled with technology a generation beyond anything the tenant could construct on the ground.

The Medium and Large zones carried advanced fabrication, nanofabrication and clean-room capability, dedicated supercomputing with AI-assisted research tools, instruments Nova had made and no one else possessed.

A pharmaceutical company leasing a zone was not simply crystallizing proteins in microgravity. It was doing all of its work with tools that made its Earth laboratories look like museums. That was the thing that turned interest into hunger. Not the absence of gravity, but the presence of Nova, rented out by the square kilometer.

And the value did not stay in orbit, which was the part that mattered most, because research that never came home was worthless. It came down as knowledge.

A company that successfully crystallizes a protein in a microgravity bay, then imaged its exact structure, and carried that structure back to Earth to design a drug that would be manufactured in an ordinary factory and given to millions. The microgravity had only been the window that let them see the thing clearly. The seeing was the product.

A materials firm that learned how an alloy wanted to form without gravity pulling it apart, then engineered an Earth process to approximate it. A biotech that studied how tissue truly assembled itself in three dimensions, and brought that understanding down into regenerative medicine and cancer research.

The discoveries traveled back to the ground as understanding, and the understanding reshaped what could be built and healed on Earth. Only a rare handful of things, the flawless fibers and certain perfect crystals, could exist nowhere but orbit and would have to be made there and shipped down—if that would be possible. Everything else came home as knowledge that changed Earth without Earth ever needing to leave the ground.

The passage between orbit and ground was not left to chance or to the slow return of personnel. Every zone carried a secure, direct line to its owner’s base on the surface, a channel down which researchers could speak with their Earth teams and share their work the moment it existed.

A structure imaged in a microgravity bay could be in the hands of a laboratory on the ground within the hour, the orbital zone and the Earth operation working as a single body across the distance rather than an outpost reporting home.

But the line had a limit, and it was not in the sending. Nova could transmit anything, instantly, cleanly. The question was whether the Earth side could receive it.

The data that would came out of a Nova-grade zone would possibly be so vast beyond ordinary measure, atomic-resolution structures, complete simulation outputs, fabrication sets of a size and complexity Earth systems had never been built to hold, and an organization could only take down as much as it had the room to store and the technology to render.

A tenant with a modest ground operation might find that the zone offered it more than its own base could catch, files it could receive but not fully open, results generated with tools a generation ahead of anything it owned below.

The zone would give everything it produced. Whether the tenant could carry all of it home depended entirely on what the tenant had built to receive it.

The better an organization’s operation on the ground, the more of the orbit it could actually bring down, and so the advanced grew more advanced still, while the rest took home only as much of the future as their own hands could yet hold.

For the universities and the research institutions, this was the chance of the century, a place to do fundamental science, physics and biology and materials and fluid dynamics, in conditions their disciplines had theorized about for generations and never touched.

For the great pharmaceutical and materials and semiconductor companies, it was something closer to a necessity, because the moment a rival began developing microgravity-crystallized drugs or space-grown semiconductors with Nova-grade tools, an Earth laboratory working a generation behind could not hope to compete.

For the pharmaceutical companies especially, there was a harder truth underneath it. The coming public rollout of Nova Medical Nanites meant the days of their dominance were numbered, and they knew it.

But numbered was not the same as ended. The nanites would take the great consumer market, the diseases and conditions that had been the industry’s fortune for a century, and there was no fighting that. What they would not take was everything.

There would always be the residual, the parts of the field the nanites did not reach or did not bother with, the veterinary and the agricultural, the research chemicals, the unsubscribed, and above all the vast portions of the developing world that the subscription price would keep locked out for a generation.

The industry would not vanish. It would shrink, and change shape, and survive in the margins the nanites left behind.

And in the near term there was a window, a real one. By the companies’ own projections, full penetration of the nanites across humanity would take the better part of a decade, held back not by the technology but by everything around it, and above all by the price.

Even at its swiftest, it would take more than ten years for the nanites to reach seventy percent of the human population. That left years in which a drug still mattered. A company that found a single breakout in the next two or three, from research it could do nowhere but a Nova zone, stood to make a fortune before the door narrowed, and to carry the capability it bought into whatever the industry became on the other side.

The zone was not a bet on the old dominance. It was a bet on the lucrative dusk of it, and on surviving into the smaller, stranger daylight that would follow.

The zones sold themselves the way the retail partnerships had, through the same quiet dread of being the one left out. Being in orbit stopped being a luxury and became the price of staying in the race.

But for the governments, the calculation carried a sting the companies did not feel, and it was written into the restrictions.

Nova forbade weapons development of any kind, and military research of any kind, regardless of how the research was framed, and it monitored every zone continuously to enforce it.

For a civilian science agency this changed nothing. A nation could put its health institute, its materials laboratory, its fundamental physics program into a zone and work freely.

But a government’s defense arm, the part of the state that would most have wanted a microgravity laboratory beyond the reach of every treaty and every inspector, was barred at the door.

Nova handed the great powers the finest research environment ever built and forbade them the one thing they would most have wanted to do in it. They could not build a single weapon there, could not run a single military program, could not frame a project cleverly enough to slip it past monitoring that never blinked.

The most powerful nations on Earth discovered that their power bought them exactly the same access as everyone else, and their militaries bought them nothing at all. It was a civilian frontier, open to all comers and closed absolutely to the one use states had always found for any new high ground.

And yet none of them stayed away, because the restriction, galling as it was, did not touch the value that made the zones worth having. That value, when the organizations finally ran it to the end, was almost difficult to hold in the mind.

A single drug designed from a protein structure that could only be seen in microgravity might be worth tens of billions of dollars across its life, and a company that could design such drugs when its rivals could not held an advantage no amount of Earth-bound spending could close.

A materials breakthrough, a better semiconductor, a superconductor, a flawless optical fiber, a regenerative therapy grown from tissue that only formed correctly in orbit, any one of them could found an industry.

The lease was ten billion dollars a year for a Large zone, and to an outsider that number looked insane. To the pharmaceutical giant weighing it against a single blockbuster drug it could develop nowhere else, it looked like the cheapest thing it had ever bought. The zones did not cost too much.

Measured against what came out of them, they were nearly free, and the organizations that understood that were already submitting, because the true danger was never the price. The true danger was a competitor securing one of the five Large zones that would never be more than five, and holding, forever, a door to the future that no amount of money could ever pry back open.

And such the frenzy to get a hold of a zone started, as the entities who could afford it, started dropping their rental applications, causing the wait-list to fill up almost immediately.